At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 65 enrolled
Drug / intervention
enzastaurin +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1/2 Trial of Enzastaurin and Erlotinib in Patients With Advanced Solid Tumors and Non-Small Cell Lung Cancer (NSCLC) After Prior Chemotherapy
In Brief
A Phase 2 clinical trial evaluating enzastaurin and erlotinib for Non-Small Cell Lung Cancer and Malignant Solid Tumor. Completed, enrolled 65 participants across 10 sites.
Detailed Summary
Phase I: A study to see what doses of Enzastaurin and Erlotinib are best tolerated by participants with solid tumor cancer. Phase II: A study to see how long participants with non-small cell lung cancer (NSCLC) treated with Enzastaurin and Erlotinib live.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNon-Small Cell Lung Cancer, Malignant Solid Tumor
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMar 2007
Enrollment StartMay 2007
Primary CompletionJul 2009
Study CompletionNov 2013
TodayJul 2026
First PostedMar 27, 2007
Enrollment StartMay 1, 2007
Primary CompletionJul 1, 2009
Study CompletionNov 1, 2013
TodayJul 2, 2026
Enrollment to primary: 2.2 yearsPosted 19.3 years ago
Interventions
enzastaurindrug
Administered orally
erlotinibdrug
Administered orally